Status:
RECRUITING
Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Conditions:
Treatment Resistant Hypertension
Chronic Hemodialysis
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study i...
Detailed Description
Patients with end-stage renal disease (ESRD) and hemodialysis have a very high risk for cardiovascular events and a very high cardiovascular mortality. Uncontrolled treatment resistant hypertension (T...
Eligibility Criteria
Inclusion
- Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg
- end-stage renal disease on chronic hemodialysis
- Stable hemodialysis regime for at least 3 months based on the decision of the treating physician
- Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.
- Individual is ≥ 18 years of age, male and female patients are included.
Exclusion
- Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient
- Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement
- Prior renal denervation procedure
- Anatomic or functional solitary kidney, kidney transplantation
- Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements
- Endocrine hypertension other than obstructive sleep apnea
- Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit
- Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months
- Subject is pregnant, nursing, or intends to become pregnant
- Enrollment in another interventional research protocol.
- Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)
Key Trial Info
Start Date :
March 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06556407
Start Date
March 4 2024
End Date
December 1 2026
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension
Erlangen, Bavaria, Germany, 91054